Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  New England Journal of Medicine

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1056/NEJMoa1002926PMID 20942659PMCID PMC3008575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids

  2010cited by this paper
• The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

  2010cited by this paper
• Genetic diagnosis by whole exome capture and massively parallel DNA sequencing

  2009cited by this paper
• Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes

  2009cited by this paper
• Exome sequencing identifies the cause of a Mendelian disorder

  2009cited by this paper
• Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)

  2009cited by this paper
• Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing

  2009cited by this paper
• Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.

  2008cited by this paper
• Hepatic proprotein convertases modulate HDL metabolism.

  2007cited by this paper
• Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

  2006cited by this paper
• Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism.

  2005cited by this paper
• Familial hypobetalipoproteinemia: genetics and metabolism

  2005cited by this paper
• Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism

  2005cited by this paper
• Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21.

  2005cited by this paper
• A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice Published, JLR Papers in Press, April 2, 2003. DOI 10.1194/jlr.M300031-JLR200

  2003cited by this paper
• Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.

  2003cited by this paper
• Angptl3 regulates lipid metabolism in mice

  2002cited by this paper
• ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase*

  2002cited by this paper
• In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.

  2000cited by this paper
• Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1-22.

  2000cited by this paper
• Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apoB gene in Caucasian families.

  1998cited by this paper
• Multipoint quantitative-trait linkage analysis in general pedigrees.

  1998cited by this paper
• Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B.

  1996cited by this paper

• A neutralizing APOA5 monoclonal antibody reduces amounts of lipoprotein lipase in capillaries and triggers hypertriglyceridemia.

  2026cites this paper
• Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent.

  2025cites this paper
• Emerging Triglyceride-Rich Lipoprotein Targeted Therapies: An Unmet Need in Cardiometabolic Disease

  2025cites this paper
• Syndromic Retinitis Pigmentosa: A Narrative Review

  2025cites this paper
• Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.

  2025cites this paper
• Combined analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics reveals the expression patterns of lipid metabolism and ferroptosis in the immune microenvironment of metabolic-associated fatty liver disease.

  2025cites this paper
• Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials

  2025cites this paper
• Genetics of remnant cholesterol.

  2025cites this paper
• Therapy for mixed dyslipidaemia through ANGPTL3 inhibition.

  2025cites this paper
• An overview of persistent chylomicronemia: much more than meets the eye

  2025cites this paper
• The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.

  2025cites this paper
• Versatile Functions of Hepatic Lipase in Lipoprotein Metabolism.

  2025cites this paper
• Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia

  2025cites this paper
• Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia

  2025cites this paper
• Pro-Inflammatory and Lipid Metabolism Dysregulating Effects of ANGPTL3 in THP-1 Macrophages

  2025cites this paper
• Associations of ANGPTL proteins and complexes with progression of coronary artery calcification and coronary events.

  2025cites this paper
• Circulating Angiopoietin-Like Protein 3 Level and Plaque Calcification: An Optical Coherence Tomography Imaging Analysis

  2025cites this paper
• Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV

  2025cites this paper
• Antibody-Based Therapeutics for Hypercholesterolemia

  2025cites this paper
• Effects of evinacumab on high-density lipoprotein function in patients with homozygous familial hypercholesterolemia.

  2025cites this paper
• ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states

  2025cites this paper
• A study into rare GPR146 gene variants in humans and mice.

  2025cites this paper
• Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomization

  2025cites this paper
• Lipid deprivation amplifies type I IFN responses in monocytes through prenylation: insights from familial combined hypolipidemia type 2

  2025cites this paper
• Multitrait analyses identify genetic variants associated with aortic valve function and aortic stenosis risk

  2025cites this paper
• Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

  2025cites this paper
• Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease.

  2025cites this paper
• The Relationship Between Arterial Stiffness and Circulating Lipids in Firefighters

  2025cites this paper
• Synergic combination of the monogenic ANGPTL3 p.H343R variant and a polygenic predisposition in a family with hypobetalipoproteinemia.

  2025cites this paper
• ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting

  2025cites this paper
• Paracrine Signaling by Distinct Adipose Tissue Depots Regulate Fibroblast Mechanobiology and Functional Heterogeneity

  2025cites this paper
• Discovery, Optimization, and Evaluation of Novel ANGPTL3 Modulators for the Treatment of Hyperlipidemia.

  2025cites this paper
• Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

  2025cites this paper
• A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II

  2025cites this paper
• The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk-reducing therapies to the novel challenging strategies.

  2025cites this paper
• ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

  2025cites this paper
• Target Populations for Novel Triglyceride-Lowering Therapies.

  2025cites this paper
• Effect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics

  2025cites this paper
• Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk.

  2025cites this paper
• Regulation of Adipose Tissue Metabolism During Fasting.

  2025cites this paper
• Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3‐LPL Axis

  2025cites this paper
• A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL‐C lowering activities in hyperlipidemia mice

  2024cites this paper
• Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets

  2024cites this paper
• Postprandial exercise regulates tissue-specific triglyceride uptake through angiopoietin-like proteins

  2024cites this paper
• ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism

  2024cites this paper
• Emerging therapies for refractory hypercholesterolemia: a narrative review.

  2024cites this paper
• Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease

  2024cites this paper
• Homozygous Familial Hypercholesterolemia Treatment: New Developments

  2024cites this paper
• Inflammatory and Lipid Biomarkers in Early Atherosclerosis: A Comprehensive Analysis

  2024cites this paper
• Phenotype in Individuals with Heterozygous Rare Variants in LIPC Encoding Hepatic Lipase

  2024cites this paper
• Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia

  2024cites this paper
• ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients

  2024cites this paper
• Impact of a post-lifestyle modification program in circulating angiopoietin-like proteins in Arab adolescents

  2024cites this paper
• Low LDL-C: Is It all Good News?

  2024cites this paper
• Recent progress in gene therapy for familial hypercholesterolemia treatment

  2024cites this paper
• Molecular diagnostics of familial hypercholesterolemia in Russia: yesterday, today and tomorrow

  2024cites this paper
• Evinacumab: Mechanism of action, clinical, and translational science

  2024cites this paper
• Therapeutic Gene Editing in Dyslipidemias

  2024cites this paper
• Genome-wide discovery and integrative genomic characterization of insulin resistance loci using serum triglycerides to HDL-cholesterol ratio as a proxy

  2024cites this paper
• Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond

  2024cites this paper
• Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation.

  2024cites this paper
• Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.

  2024cites this paper
• Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1

  2024cites this paper
• Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA).

  2024cites this paper
• Integrated Whole Exome and Transcriptome Sequencing in Cholesterol Metabolism in Melanoma: Systematic Review

  2024cites this paper
• ANGPTL3 is a novel HDL component that regulates HDL function

  2024cites this paper
• Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.

  2024cites this paper
• The Role of Genetics in Advancing Cardiometabolic Drug Development

  2024cites this paper
• A deep catalogue of protein-coding variation in 983,578 individuals

  2024cites this paper
• Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease

  2024cites this paper
• Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?

  2024cites this paper
• Metabolism and Clinical Significance of Triglycerides

  2024cites this paper
• Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk

  2024cites this paper
• L’évinacumab : un nouveau médicament dans l’arsenal thérapeutique de l’hypercholestérolémie réfractaire

  2024cites this paper
• Drug development advances in human genetics‐based targets

  2024cites this paper
• Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.

  2024cites this paper
• Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.

  2024cites this paper
• The serum levels of angiopoietin‐like protein 3 and 4 in type 2 diabetic patients with and without metabolic syndrome compared to the control group

  2023cites this paper
• Serum Angiopoietin-like Protein 3 Levels Are Associated with Endothelial Function in Patients with Maintenance Hemodialysis

  2023cites this paper
• Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia

  2023cites this paper
• Genome Editing in Dyslipidemia and Atherosclerosis.

  2023cites this paper
• The GPIHBP1-LPL complex and its role in plasma triglyceride metabolism: Insights into chylomicronemia.

  2023cites this paper
• ANGPTL3 (Angiopoietin‐Like 3) Preferentially Resides on High‐Density Lipoprotein in the Human Circulation, Affecting Its Activity

  2023cites this paper
• Association of Genotypes of ANGPTL3 with Vitamin D and Calcium Concentration in Cardiovascular Disease

  2023cites this paper
• ATVB IN FOCUS: Emerging Genomic-Based Therapies for Cardiovascular Disease

  2023cites this paper
• Rare predicted loss of function alleles in Bassoon (BSN) are associated with obesity

  2023cites this paper
• Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3.

  2023cites this paper
• Angiopoietin-like 3 inhibition and the liver: less is more?

  2023cites this paper
• The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

  2023cites this paper
• Playing the genetic lottery: an interview with Kiran Musunuru

  2023cites this paper
• New and Emerging Therapies for Dyslipidemia

  2023cites this paper
• How ANGPTL3 Inhibition Will Help Our Clinical Practice?

  2023cites this paper
• Generation of a familial hypercholesterolemia model in non-human primate

  2023cites this paper
• Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease.

  2023cites this paper
• The Dawn of In Vivo Gene Editing Era: A Revolution in the Making

  2023cites this paper
• Severe hypertriglyceridemia: Existing and emerging therapies.

  2023cites this paper
• The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy

  2023cites this paper
• Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

  2023cites this paper
• Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events.

  2023cites this paper
• From target discovery to clinical drug development with human genetics

  2023cites this paper